Bruce Neal's Publications

About Bruce Neal's Publications

Executive Director, The George Institute for Global Health, Australia
  • Measuring the healthiness of ready-to-eat child-targeted cereals, a study of the FoodSwitch platform in Sweden (Preprint)

    JMIR mHealth and uHealth Date published:
  • A Systematic Review of the Sources of Dietary Salt Around the World

    Advances in Nutrition Date published:
  • Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program

    Diabetes, Obesity and Metabolism Date published:
  • Harnessing the power of coherent and coordinated food policies

    Date published:
  • Independent predictors of heart failure in patients with type 2 diabetes and chronic kidney disease: modeling from the CREDENCE trial

    Date published:
  • The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: analysis of the CREDENCE trial

    Date published:
  • Acute declines in eGFR during treatment with canagliflozin and its implications for clinical practice: insights from CREDENCE

    Date published:
  • CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL

    Date published:
  • CANAGLIFLOZIN (CANA) REDUCES CARDIOVASCULAR (CV) AND RENAL EVENTS INDEPENDENT OF BASELINE HEART FAILURE (HF): A CREDENCE SECONDARY ANALYSIS

    Date published:
  • EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL

    Date published:
  • EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIFFERENT BASELINE LEVELS OF TYPE 2 DIABETES MELLITUS DISEASE SEVERITY: RESULTS FROM THE CANVAS PROGRAM

    Date published:
  • Contribution of major food companies and their products to household dietary sodium purchases in Australia

    Unknown Date published:
  • The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program

    The Lancet Rheumatology Date published:
  • Front-of-pack nutrition labelling to promote healthier diets: current practice and opportunities to strengthen regulation worldwide

    BMJ Global Health Date published:
  • Do GLP-1 Receptor Agonists Care if You Have Heart Failure?

    Circulation Date published:
  • SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

    The Lancet Diabetes & Endocrinology Date published: